CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 144 enrolled
Drug / intervention
doxazosin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02500602
NCT02500602Phase 2Completed
CompareCT.gov

CAP - Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

VA Office of Research and Development·interventional·Posted Jul 16, 2015·Updated May 13, 2021

In Brief

A Phase 2 clinical trial evaluating doxazosin and placebo for Posttraumatic Stress Disorder and Alcohol Use Disorders. Completed, enrolled 144 participants across 1 site.

Detailed Summary

The proposed study will examine the efficacy of doxazosin in the treatment of PTSD and alcohol use disorder or substance use disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPosttraumatic Stress Disorder, Alcohol Use Disorders
CountriesUnited States
CollaboratorsMedical University of South Carolina

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 16, 2015
Enrollment StartJun 1, 2016
Primary CompletionDec 16, 2019
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 11.0 years ago

Interventions

doxazosindrug

active medication

placebodrug

placebo pill